SCOTT WEPFER, RPH
Pharmacy at Independence Dr, Birmingham, AL
License number
Alabama 11759
Category
Pharmacy
Type
Pharmacist
Address
Address
3349 Independence Dr SUITE 102, Birmingham, AL 35209
Phone
(205) 870-3150
(205) 870-3160 (Fax)
(205) 870-3160 (Fax)
Personal information
See more information about SCOTT WEPFER at radaris.comName
Address
Phone
3209 Heathrow Downs, Hoover, AL 35226
3209 Heathrow Downs, Hoover, AL 35226
1209 Heathrow Down, Birmingham, AL 35226
Professional information
See more information about SCOTT WEPFER at trustoria.com
President At The Compounding Shoppe
President At The Compounding Shoppe
Position:
President at The Compounding Shoppe, Owner at The Compounding Shoppe
Location:
Birmingham, Alabama Area
Industry:
Pharmaceuticals
Work:
The Compounding Shoppe
-
President
The Compounding Shoppe
since 1995
-
Owner
Education:
University of Wisconsin-Madison 1984 - 1989
BS, Pharmacy
BS, Pharmacy
Topical Anesthetic Formulation
Topical Anesthetic Formulation
US Patent:
7273887, Sep 25, 2007
Filed:
Oct 23, 2000
Appl. No.:
10/111241
Inventors:
Scott Wepfer - Hoover AL, US
Assignee:
Transdermatech, Inc. - Tuscaloosa AL
International Classification:
A61K 31/24, A61K 31/16, A61K 9/07
US Classification:
514535, 514536, 514537, 514626, 424449
Abstract:
The topical anesthetic formulation of the present invention is typically a solution that preferably includes lidocaine, USP as the active anesthetic ingredient with benzyl alcohol and isopropyl alcohol. This invention deals with problems commonly associated with topical application of local anesthetics such as: slow onset of action; need for occlusion; messiness of creams, ointments or gels; and rapid loss of effect due to rapid systemic dispersion. The invention permits enhanced penetration of the anesthetic and thereby allows for a lesser total dosage of pharmaceutically active ingredient. The use of a lesser total dosage also decreases systemic toxicity.
Topical Anesthetic Formulation
Topical Anesthetic Formulation
US Patent:
2007026, Nov 22, 2007
Filed:
Aug 8, 2007
Appl. No.:
11/835500
Inventors:
Scott Wepfer - Birmingham AL, US
International Classification:
A61K 38/14, A61P 23/02, A61P 25/04, A61P 25/08, A61P 3/02, A61P 31/04, A61P 31/12, A61K 31/7048, A61K 31/7034, A61K 31/496
US Classification:
424059000, 514626000, 514724000, 514730000, 514781000, 514154000, 514035000, 514008000, 514029000, 514192000, 514200000, 514253080
Abstract:
The topical medicament gel formulation of the present invention includes an anesthetic, an anti-microbial, an oxidant, a nutrient, a diuretic, an opioid, an anti-emetic, an anti-seizure drug, and a non-steroidal anti-inflammatory drug (NSAID), USP in a molecular, as opposed to a salt form, as the active ingredient. Additional constituents illustratively include a skin penetration enhancer and a gelling agent. This invention deals with problems commonly associated with topical application of local medicaments such as: slow onset of action; need for occlusion; and rapid loss of effect due to rapid systemic dispersion. The invention permits enhanced penetration of the medicament and thereby allows for a lesser total dosage of pharmaceutically active ingredient. The use of a lesser total dosage also decreases systemic toxicity.
Topical Anesthetic Formulation
Topical Anesthetic Formulation
US Patent:
2004013, Jul 8, 2004
Filed:
Aug 22, 2003
Appl. No.:
10/645951
Inventors:
Scott Wepfer - Hoover AL, US
International Classification:
A61K009/70, A61K031/24
US Classification:
424/449000, 514/536000
Abstract:
The topical anesthetic gel formulation of the present invention preferably includes lidocaine, USP as the active anesthetic ingredient with a skin penetration enhancer and a gelling agent. This invention deals with problems commonly associated with topical application of local anesthetics such as: slow onset of action; need for occlusion; messiness of creams, ointments or gels; and rapid loss of effect due to rapid systemic dispersion. The invention permits enhanced penetration of the anesthetic and thereby allows for a lesser total dosage of pharmaceutically active ingredient. The use of a lesser total dosage also decreases systemic toxicity.